The time for you to tumor progression ranged from 0. five to 12 months. Survival ranged from 0. 5 to 24 six months, 6 month and twelve month PFS rates had been 43% and 3%, respec tively. CPT eleven demonstrated modest efficacy with acceptable toxicity within this cohort of grownup patients with recurrent anaplastic astrocytoma, all of whom had failed previous TMZ chemotherapy. TA 10. PRELIMINARY PHASE I Results On the NOVEL ANTHRACYCLINE RTA 744 IN Patients WITH Major BRAIN TUMORS Charles Conrad, Christina Meyers, Timothy Madden, Waldemar Priebe, Patricia Gaupp, Karen Rohan, Christiane Baud, The University of Texas M. D. Anderson Cancer Center, Houston, TX, Reata Pharmaceuticals, Dallas, TX, USA RTA 744 can be a novel anthracycline that has been proven in preclinical scientific studies to cross the blood brain barrier and enhance survival in an ortho topic murine model of glioblastoma multiforme. The initial human trial of RTA 744 was initiated at M.
D. Anderson Cancer Center in individuals with primary substantial grade gliomas. Individuals get RTA 744 as a 2 hour intravenous infusion on every single within the initially 3 days of a 21 day cycle. Dose escalation is proceeding according to an accelerated titration design with single patient cohorts and 100% dose escalation actions until eventually first evidence selleck VEGFR Inhibitors of drug connected grade II or greater toxicities. The MTD is defined as the dose at which 1/6 individuals experiences a DLT with a minimum of 2/6 experiencing a DLT at the up coming higher dose degree. The MTD is currently being determined first in individuals who usually do not take enzyme inducing anti convulsants. A second cohort of individuals who do take these medications is planned. Pharmacoki netic samples are remaining taken multiple occasions on days one five of Cycle 1. Tumor exercise is getting assessed in accordance towards the MacDonald criteria.
As of May possibly 2006, RTA 744 continues to be administered to a total of 7 individuals at dose ranges of one. two, two. four, four. eight, and 9. 6 mg/m2/day. No grade 2 or better drug relevant toxicities are actually observed at doses of 4. 8 mg/m2 and beneath, success at 9. six mg/m2 are pending. The pharmacokinetic profile signifies dose proportionality with some accumulation by day 3. Plasma half life of RTA 744 is somewhere around thirty hours. 3 on the initially 4 patients selleck chemicals AZD3463 received not less than 4 cycles, and one of these individuals remains enrolled while in the research. Proof of clinical action was also seen from the initially 4 sufferers, includ ing two minor responses and one secure ailment. One of the most recent patient received a dose four times the level at which tumor regression was 1st documented. The results of MRI scans from your 2 most lately

enrolled individuals are pending. RTA 744 is well tolerated at doses of four. 8 mg/m2/day, has superior pharmacokinetics, and shows early proof of activity. Dose escalation should continue to define the MTD.